Chinese Medical Sciences Journal ›› 2010, Vol. 25 ›› Issue (3): 140-145.doi: 10.1016/S1001-9294(10)60038-7

• Original Article • Previous Articles     Next Articles

The St. George’s Respiratory Questionnaire in Lymphangioleiomyomatosis

Kai-feng Xu*, Lan Wang, Xin-lun Tian, Yao-song Gui, Min Peng, Bai-qiang Cai, and Yuan-jue Zhu   

  1. Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
  • Received:2010-02-24 Online:2010-09-20 Published:2010-09-20
  • About author:Tel: 86-10-65295039, Fax: 86-10-65231169

Abstract: Objective To examine the correlation between the health-related quality of life measured by the St. George's Respiratory Questionnaire (SGRQ) and the commonly used physiological measures in lymphangioleiomyomatosis (LAM). Methods This study retrospectively analyzed the SGRQ scores and other measures (the Borg scale of breathlessness at rest, 6-minute walking distance, blood oxygen levels, and pulmonary function) of patients diagnosed and confirmed with LAM. Altogether 38 patients between June 2007 and November 2009 were included. Results The mean values of the SGRQ three components (symptoms, activity, and impacts) and total scores in the LAM patients were 46.9528.90, 58.4725.41, 47.8929.66, and 51.1126.35, respectively. The SGRQ total or component scores were correlated well with the Borg scale of breathlessness, 6-minute walking distance, partial pressure of oxygen in arterial blood, spirometry and diffusion capacity of lung. There were poor correlations between SGRQ score and residual volume or total lung capacity. In our preliminary observation, sirolimus improved the SGRQ total and three component scores and the Borg scale of breathlessness significantly after 101-200 days of treatment (n=6). Conclusions The SGRQ score in LAM is correlated well with physiological measures (Borg scale of breathlessness, 6-minute walking distance, blood oxygen levels, and pulmonary function tests). The SGRQ could therefore be recommended in baseline and follow-up evaluation of patients with LAM. Treatment with sirolimus, an inhibitor of mammalian target of rapamycin, may improve the quality of life and patient's perception of breathlessness in LAM.

Key words: lymphangioleiomyomatosis, St. George's Respiratory Questionnaire, pulmonary function, quality of life, sirolimus


Supported by National Basic Research Program of China (973 Program) (2009CB522106).

Copyright © 2021 Chinese Academy of Medical Sciences.  京公安备110402430088  京ICP备06002729号-1  Powered by Magtech.

Supervised by National Health Commission of the People's Republic of China

9 Dongdan Santiao, Dongcheng district, Beijing, 100730 China

Tel: 86-10-65105897  Fax:86-10-65133074 


Copyright © 2018 Chinese Academy of Medical Sciences

All right reserved.

京公安备110402430088  京ICP备06002729号-1